Crescendo Biologics Limited has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. These ‘triple knockout’ mice are believed to be unique.
29 September, 2010
Ghent University, the University of Antwerp and BioTools Europe Ltd have partnered to create the European Centre for Chirality (EC2), which is dedicated to advancing understanding of the part chirality plays in biological processes.
24 September, 2010
AstraZeneca’s new oral syk inhibitor, fostamatinib (R788), significantly improves outcomes of patients with rheumatoid arthritis who respond inadequately to methotrexate, according to phase II study data.
22 September, 2010
EFPIA, the voice of the research-based pharmaceutical industry in Europe, has welcomed the European Parliament’s adoption of the Commission’s proposal on pharmacovigilance.
22 September, 2010
Researchers have created a draft genome sequence for the endangered Tasmanian devil and will use this to find genetic mutations in the transmissible cancer ravaging its population.
17 September, 2010
Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a gruelling thousand mile charity bike ride to raise £5000 for Marie Curie Cancer Care.
16 September, 2010
Cancer Research UK and Cancer Research Technology have reached an agreement with AstraZeneca to take compound AZD-3965, a first-of-its-kind experimental drug that could treat a range of cancers, into clinical trial.
13 September, 2010
Newly published sub-group analysis from the landmark RE-LY® study has shown dabigatran etexilate significantly reduces the risk of stroke compared to warfarin, irrespective of centre-based international normalized ratio control.
13 September, 2010
The compelling arguments for the use of pharmacogenetics in drug development are well known and rehearsed.
10 September, 2010
An invasive species of shrimp, commonly known as the ‘killer shrimp’, has been found at Grafham Water reservoir in Cambridgeshire – the first time the shrimp has been found in the UK.
10 September, 2010
A recent clinical research paper indicates that IMP321 combined with paclitaxel has achieved clinical benefit in 90 per cent of patients in first-line metastatic breast cancer.
09 September, 2010
Charles River Laboratories, a global preclinical contract research organization, now offers BlueScreen HC Screening services for the early detection of genotoxicity.
09 September, 2010
The combined effects of numerous single-letter changes in several genes could be used to predict a woman’s risk of developing the most common form of breast cancer – oestrogen-receptor-positive breast cancer.
07 September, 2010
MorphoSys AG has announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics.
03 September, 2010
Scientists have discovered a true counterpart of the cerebral cortex in an invertebrate (a marine worm), which gives an idea of what the most ancient higher brain centres looked like.
02 September, 2010
Cyprotex is giving researchers free online access to its database of the ADME and pharmacokinetic properties of marketed drugs via its online Cloe® Knowledge data visualization and interpretation tool.
01 September, 2010